Skyrizi vs Cosentyx
Risankizumab vs Secukinumab · Comparison Guide
Quick Comparison
| Feature | Skyrizi | Cosentyx |
|---|---|---|
| Generic Name | Risankizumab | Secukinumab |
| Manufacturer | AbbVie | Novartis |
| Drug Class | IL-23 Inhibitor | IL-17A Inhibitor |
| Shared Conditions | Plaque Psoriasis | |
Key Differences: Skyrizi vs Cosentyx
These medications target different cytokines (IL-23 vs IL-17A). For psoriasis, indirect comparisons suggest IL-23 inhibitors like Skyrizi may achieve higher PASI 90/100 rates than IL-17A inhibitors like Cosentyx. Cosentyx is generally safe in IBD-negative patients; Skyrizi is approved for Crohn's. Skyrizi requires fewer injections (every 12 weeks vs monthly).
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
💊 Cosentyx (Secukinumab)
- Class: IL-17A Inhibitor
- Manufacturer: Novartis
- Full Cosentyx information →
These medications target different cytokines (IL-23 vs IL-17A). For psoriasis, indirect comparisons suggest IL-23 inhibitors like Skyrizi may achieve higher PASI 90/100 rates than IL-17A inhibitors like Cosentyx. Cosentyx is generally safe in IBD-negative patients; Skyrizi is approved for Crohn's. Skyrizi requires fewer injections (every 12 weeks vs monthly).
Neither Skyrizi nor Cosentyx is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Skyrizi and Cosentyx are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Skyrizi and Cosentyx both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Skyrizi and Cosentyx
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Skyrizi and Cosentyx should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.